ARCHIVES

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

This article is from The Cancer Letter archive.

Vol. 03 No. 40 | October 7, 1977

Download PDF Visit The Full Archive

Related Articles

Penn Begins Clinical Trial Of A Vaccine For Breast Cancer Based On Telomerase

February 27, 2004

Flood Mistrial

February 9, 1979

Drug Approvals: FDA Approves Vectibix in mCRC With KRAS Companion Diagnostic

May 30, 2014

CTCs Do Not Affect Survival, But Could Signal Metastases

December 30, 2011

Study Links Exercise and Survival In Breast and Colon Cancer Mortality

May 25, 2012

New CCSP And CCRU Awards Applications Under Review

January 17, 1986